Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia

Leukemia

Volumn 18, Issue 8, 2004, Pages 1340-1346

  Terre, C ^a   Eclache, V ^b   Rousselot, P ^c   Imbert, M ^d   Charrin, C ^e   Gervais, C ^f   Mozziconacci, M J ^g   Maarek, O ^c   Mossafa, H ^h   Auger, N ⁱ   Dastugue, N ^j   Talmant, P ^k   Van den Akker, J ^l   Leonard, C ^m   N'Guyen Khac, F ⁿ   Mugneret, F ^o   Viguie F ^p   Lafage Pochitaloff, M ^g   Bastie, J N ^a   Roux, G L ^b   Nicolini, F ^e   Maloisel, F ^f   Vey, N ^g   Laurent, G ^j   Recher, C ^j   Vigier, M ^k   Yacouben, Y ^d   Giraudier, S ^d   Vernant, J P ⁿ   Salles, B ^o   Roussi, J ^p   Castaigne, S ^a   Leymarie, V ^f   Flandrin, G ^q   Lessard, M ^f   more..

^a CENTRE HOSPITALIER DE VERSAILLES   (France)

^b AVICENNE HOSPITAL   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e EDOUARD HERRIOT HOSPITAL   (France)

^f HÔPITAL DE HAUTEPIERRE   (France)

^g INSTITUT PAOLI CALMETTES   (France)

^h Cytogenetic and Clincial Departments   (France)

ⁱ PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^j CHU PURPAN   (France)

^k HÔTEL DIEU   (France)

^l HÔPITAL SAINT ANTOINE   (France)

^m BICÊTRE HOSPITAL   (France)

ⁿ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^o HÔPITAL DU BOCAGE   (France)

^p HÔTEL DIEU   (France)

^q HÔPITAL NECKER ENFANTS MALADES   (France)

more..

Author keywords

Clonal chromosomal abnormalities; CML; Imatinib

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CYTARABINE; HYDROXYUREA; IMATINIB;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOGENETICS; CYTOLOGY; DISEASE DURATION; DRUG RESPONSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MALE; MONOSOMY 7; MYELODYSPLASIA; OUTCOMES RESEARCH; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TRISOMY 8;

EID: 4344638050     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403399     Document Type: Article

References (33)

1. Champlin RE, Golde DW. Chronic myelogenous leukemia: recent advances. Blood 1985; 65: 1039-1047.
2. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of ABL and BCR genes in chronic myelogenous leukemia. Nature 1985; 315: 550-554.
3. Kantarjian H, Sawyers C, Hochlaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645-652.
4. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
5. Casali M, Truglio F, Milone G, Di Raimondo F, Parinello G, Maserati E et al. Trisomy 8 in Philadelphia chromosome (Ph 1)-negative cells in the course of Ph1-positive chronic myelocytic leukemia. Genes Chromosomes Cancer 1992; 4: 269-270.
6. Bilhou-Nabera C, Marit G, Devianne I, Viard F, Salzes S, Montastruc M et al. A second case of trisomy 8 in Philadelphia chromosome (Ph)-negative cells during the course of Ph-positive chronic myelocytic leukemia. Genes Chromosomes Cancer 1993; 4: 255-256.
7. Ariyama T, Inazawa J, Uemura Y, Kakazu N, Maekawa T, Urase FK et al. Clonal origin of Philadelphia chromosome negative cells with trisomy 8 appearing during the course of α-interferon therapy for Ph positive chronic myelocytic leukemia. Cancer Genet Cytogenet 1995; 81: 20-23.
8. Ohtuska E, Kikuchi H, Abe Y, Moriyama K, Ohno E, Hirota K et al. Acute myeloblastic leukemia without Philadelphia chromosome developing after interferon therapy for chronic myelocytic leukemia with Philadelphia chromosome. Br J Haematol 1995; 90: 951-953.
9. Izumi T, Imagawa S, Hatatake H, Miura Y, Ariyama T, Inazawa J et al. Philadelphia chromosome-negative cells with trisomy 8 after busulfan and interferon treatment of Ph1-positive chronic myelogenous leukemia. Int J Hematol 1996; 64: 73-77.
10. Fayad L, Kantarjian H, O'Brien S, Seong D, Keating M, Talpaz M. Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases. Leukemia 1997; 11: 767-771.
11. Marktel S, Bua M, Marin D, Chase A, Udom C, Armstrong L et al. Emergence of additional chromosomal abnormalities following treatment with STI571 (Imatinib Mesylate) for Philadelphia positive chronic myeloid leukemia in chronic phase. Blood 2001; 98: 617a (abstr.).
12. Gambarcoti-Passeri C, Giudici G, le Coutre P, Bungaro S, Pogliani EM, Kreuzer KA et al. Non random chromosomal abnormalities in Ph-negative bone marrow (BM) cells from CML patients achieving major cytogenetic response (MCR) with STI571 (GleevecTM). Blood 2001; 98: 257b (abstr.).
13. Meunier V, Giraudier S, Van den Akker J, Perot C, Jouault H, Caron-Servan B et al. Treatment with STI571 (Novartis) in chronic myeloid leukemia (CML): unexpected hematological findings in a series of 26 patients. Blood 2001; 98: 263b (abstr.).
14. Braziel R, Launder M, Druker B, Olson S, Magenis E, Mauro M et al. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months experience. Blood 2002; 100: 435-441.
15. Andersen MK, Pedersen-Bjergaard J, Kjeldsen L, Dufva IH, Brondum-Nielsen K. Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8. Leukemia 2002; 16: 1390-1393.
16. Bumm T, Müller C, Al-Ali HF, Krohn K, Shepherd P, Schmidt E et al. Emergence of clonal cytogenetic abnormalities in Ph-negative cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003; 101: 1941-1949.
17. Feldman E, Najfeld V, Schuster M, Roboz G, Chadburn A, Goodman O et al. The emergence of Philadelphia chromosome (Ph) negative trisomy 8 cells in patients treated with imatinib mesylate: clinical evidence for a multistep pathogenesis. Blood 2002; 100: 2299 (abstr.).
18. Meeus P, Demuynck H, Martiat P, Michaux L, Wouters E, Hagemeijer A. Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with Imatinib. Leukemia 2003; 17: 465-467.
19. Schoch C, Haferlach T, Kern W, Schnittgers S, Berger U, Hehlmann R et al. Occurence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate. Leukemia 2003; 17: 461-463.
20. O'Dwyer M, Gatter K, Loriaux M, Druker B, Olson S, Magenis E et al. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia 2003; 17: 481-487.
21. - cells of patients on imatinib. Blood 2003; 102: 2700-2701.
22. Medina J, Kantarajian H, Talpaz M, O'Brien S, Garcia-Manero G, Giles F et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during Imatinib Mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer 2003; 98: 1905-1911.
23. Sehested J. A simple method for R-banding of human chromosomes, showing a pH-dependent connection between R and G bands. Humangentik 1975; 21: 55-58.
24. Wiktor A, Rybicki B, Prao Z, Shurafa M, Barthel B, Maeda K et al. Clinical significance of Y chromosome loss in hematologic disease. Genes Chromosomes Cancer 2000; 27: 11-16.
25. Maserati E, Aprili F, Vinante F, Locatelli F, Amendola G, Zatterale A et al. Trisomy 8 in myelodysplasia and acute leukaemia is constitutional in 15-20% of cases. Genes Chromosomes Cancer 2002; 33: 93-97.
26. Chandley AC, Hargreave TB, Fletcher JM, Soos M, Axworthy D, Price WH. Trisomy 8. Report of a mosaic human male with near-normal phenotype and normal IQ, ascertained through infertility. Hum Genet 1980; 55: 31-38.
27. Baskaran R, Wood LD, Whitaker LL, Canman CE, Morgan SE, Xu Y et al. Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature 1997; 387: 516-519.
28. Kharbanda S, Pandey P, Jin S, Inoue S, Bharti A, Yuan ZM et al. Functional interaction between DNA-PK and c-Abl in response to DNA damage. Nature 1997; 386: 732-735.
29. Shafman T, Khanna KK, Kedar P, Spring K, Kozlov S, Yen T et al. Interaction between ATM protein and c-Abl in response to DNA damage. Nature 1997; 387: 520-523.
30. Yuan ZM, Huang Y, Ishiko T, Nakada S, Utsugisawa T, Kharbanda S et al. Regulation of Rad51 function by c-Abl in response to DNA damage. J Biol Chem 1998; 273: 3799-3802.
31. Chen G, Yuan SS, Liu W, Xu Y, Trujillo K, Song B et al. Radiation-induced assembly of Rad21 and rad52 combination complex requires ATM and c-Abl. J Biol Chem 1999; 274: 12748-12752.
32. Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin WG, Levrero M et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 1999; 399: 806-809.
33. Yuan ZM, Shioya H, Ishiko T, Sun X, Gu J, Huang YY et al. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 1999; 399: 814-817.